https://icotherapeutics.com/ 2022-04-21T23:40:01+00:00 https://icotherapeutics.com/2025/11/04/med-supply-drive-canadian-pharmacy-service/ 2025-11-21T11:50:18+00:00 https://icotherapeutics.com/health/how-inflation-impacts-medication-purchasing-in-north-america/ 2025-07-23T11:37:28+00:00 https://icotherapeutics.com/sildenafil-viagra 2024-12-19T12:39:15+00:00 https://icotherapeutics.com/ico-investor/happy-family-store 2026-04-29T18:18:18+00:00 https://icotherapeutics.com/2024/07/30/carc-online-pharmacy-services-and-canadian-drugs/ 2025-02-18T14:31:58+00:00 https://icotherapeutics.com/amp-b/ 2023-09-21T08:03:43+00:00 https://icotherapeutics.com/development-of-research 2025-09-02T13:49:27+00:00 https://icotherapeutics.com/problem-of-drug-shortages/ 2023-01-12T13:29:44+00:00 https://icotherapeutics.com/health/how-to-make-sure-that-generic-drugs-are-safe-for-your-health/ 2024-03-01T05:54:47+00:00 https://icotherapeutics.com/sitemap/ 2022-08-18T13:14:45+00:00 https://icotherapeutics.com/health/liver-failure-symptoms-medications-prevention/ 2024-05-01T11:13:03+00:00 https://icotherapeutics.com/ico-investor/ 2024-07-18T10:29:14+00:00 https://icotherapeutics.com/ico-008/ 2022-04-22T13:16:45+00:00 https://icotherapeutics.com/contact/ 2022-04-22T15:32:34+00:00 https://icotherapeutics.com/financial-information/ 2022-04-22T11:31:22+00:00 https://icotherapeutics.com/events-presentations/ 2022-04-22T14:25:40+00:00 https://icotherapeutics.com/articles/ 2026-06-04T09:34:10+00:00 https://icotherapeutics.com/accomplishments/ 2022-04-22T15:31:13+00:00 https://icotherapeutics.com/our-team/ 2022-04-22T09:25:06+00:00 https://icotherapeutics.com/current-assets/ 2022-04-22T13:54:15+00:00 https://icotherapeutics.com/about/ 2022-04-21T23:48:48+00:00 https://icotherapeutics.com/investor_relations/news_releases/2013/index.php 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2017/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2018/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2015/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2016/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/agm/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/newsroom/2014/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/company/our_busines_model/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/newsroom/2013/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/news_releases/2013/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/ideal/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/newsroom/2012/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/news_releases/2012/ 2022-04-23T17:12:10+00:00 https://icotherapeutics.com/alliances_and_global_licensing/strategic_advisory_board/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/alliances_and_global_licensing/professional_advisors/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/alliances_and_global_licensing/partnering/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/pipeline/oral_amphotericin/ 2022-04-23T17:12:12+00:00 https://icotherapeutics.com/newsroom/2009/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2007/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2011/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2010/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/2008/ 2022-04-23T17:15:13+00:00 https://icotherapeutics.com/pipeline/clinical_trials/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/pipeline/ico009/ 2022-04-23T17:12:12+00:00 https://icotherapeutics.com/pipeline/ico008/ 2022-04-23T17:12:12+00:00 https://icotherapeutics.com/pipeline/ico007/ 2022-04-23T17:12:12+00:00 https://icotherapeutics.com/investor_relations/news_releases/2011/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/investor_relations/news_releases/2010/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/investor_relations/news_releases/2009/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/investor_relations/news_releases/2008/ 2022-04-23T17:15:12+00:00 https://icotherapeutics.com/investor_relations/news_releases/2007/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/investor_relations/research/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/reports_and_financials/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/presentations/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/media_coverage/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/investor_relations/faq/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/disclaimer/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/corporate_video/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/investor_relations/events/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/science/ 2022-04-23T17:12:12+00:00 https://icotherapeutics.com/pipeline/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/newsroom/ 2022-04-23T17:12:11+00:00 https://icotherapeutics.com/investor_relations/news_releases/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/careers/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/alliances_and_global_licensing/ 2022-04-23T17:12:09+00:00 https://icotherapeutics.com/site/corporate_overview/corporate_video/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_phase_1_dme_clinical_trial_update_and_phase_2_tri/ 2022-04-23T17:09:04+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_closes_non-brokered_private_placement/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_diabetic_macular_edema_clinical_trial_update/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_publishes_review_of_diabetic_retinopathy_treatment/ 2022-04-23T17:09:04+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_oral_anti-parasitic_drug_to_be_presented_at_global_health_ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_ico-007_second_cohort_results_to_be_presented_at_cleveland/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_grants_options_to_new_directors/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_ico_007_results_to_be_presented_at_prestigious_ocular_conf/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_closes_13_million_private_placement/ 2022-04-23T17:09:02+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_closes_first_tranche_of_non_brokered_private_placement/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_elects_dr_richard_w_barker_and_william_jarosz_as_indep_dir/ 2022-04-24T20:10:02+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_announces_strategic_advisory_team/ 2022-04-24T20:10:56+00:00 https://icotherapeutics.com/site/investor-relations/world_renowned_retinal_specialist_joins_ico_therapeutics_strategic_advisory/ 2022-04-24T20:10:16+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_selects_isis_pharmaceuticals_to_manufacture_and_supply_ico/ 2022-04-24T20:10:25+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_appoints_expert_immunology_and_ophthalmology_chief_science/ 2022-04-24T20:11:10+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_appoints_chief_medical_officer/ 2022-04-24T20:11:17+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_welcomes_dr_david_s_boyer_to_strategic_advisory_board/ 2022-04-24T20:11:22+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_recruits_leading_ophthalmologist_to_strategic_advisory_brd/ 2022-04-24T20:10:45+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_oral_amphotericin_b_poster_at_aaps/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_third_quarter_financial_results/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_oral_amphotericin_b_effective_against_visceral_leishmanias/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_009_oral_amphotericin_b_pharmacokinetic_resul/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_to_present_at_biocontact_quebec/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_interim_trial_results_diffuse_diabetic_macular_ed/ 2022-04-23T17:09:04+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_outlines_steps_to_first_ico_009_human_clinical_trial/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_second_quarter_financial_results/ 2022-04-23T17:09:04+00:00 https://icotherapeutics.com/site/investor-relations/press_releases_archive/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_appoints_mr_noel_hall_and_dr_christian_fibiger_to_board/ 2022-04-23T17:09:02+00:00 https://icotherapeutics.com/site/pipeline/ico007/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/terms_of_use/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/pipeline/ico008/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/pipeline/ico009/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/pipeline/antisense_technology/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/investor-relations/media_coverage/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/investor_relations_overview/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/upcoming_events/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/pipeline/clinical_trials/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/investor-relations/press_releases/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_reports_new_ico_009_oral_amphotericin_b_preclinical_result/ 2022-04-23T17:09:04+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_closes_1140450_financing/ 2022-04-23T17:09:02+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_announces_1140450_financing/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_first_quarter_financial_results/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_acquires_worldwide_rights_to_ico_009_oral_amphotericin_b/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_to_present_at_biofinance_20081/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_year_end_2007_financial_results/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_ico_007_diabetic_macular_edema_poster_presentation_at_arvo/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_announces_ico_009_oral_amphotericin_b_fda_meeting/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_ico_009_oral_amphotericin_b_published_in_leading_drug_deli/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_announces_cmo_invited_to_present_at_international_ocular_c/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_009_oral_amphotericin_b_update/ 2022-04-23T17:09:03+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_and_beanstalk_capital_announce_completion_of_arrangement/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/beanstalk_capital_ltd_and_ico_therapeutics_inc_amend_arrangement_agreement/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/beanstalk_capital_ltd_enters_into_arrangement_agreement_with_ico_therapeuti/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/investor-relations/isis_receives_125_million_milestone_payment_from_ico_for_initiation_of_phas/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/news_media/upcoming_events/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/corporate_overview/board_of_directors/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/corporate_overview/partnering_strategy/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/corporate_overview/professional_advisors/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/corporate_overview/management_team/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/science/antisense_technology/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/news_media/media_coverage/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/careers/about_vancouver/ 2022-04-23T17:10:27+00:00 https://icotherapeutics.com/site/development_programs/clinical_trials/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/news/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/development_programs/ico007/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/corporate_overview/overview/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/careers/current_opportunities/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/corporate_overview/strategic_advisory_board/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/contact_us/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/news_media/press_releases 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/corporate_overview/strategic_advisors/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/corporate_overview/board_of_directors/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/corporate_overview/advisors/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/corporate_overview/partnering_strategy/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/development_programs/clinical_trials/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/corporate_overview/management_team/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_receives_fda_clearance_to_initiate_clinical_trial_in_diabe/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_receives_fda_clearance_to_initiate_clinical_trial_in_diabe/ 2022-04-23T17:09:04+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_announces_licensing_deal/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/ico_therapeutics_announces_licensing_deal/ 2022-04-23T17:09:02+00:00 https://icotherapeutics.com/site/news_media/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/ 2022-04-23T17:09:05+00:00 https://icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/ 2022-04-23T17:09:01+00:00 https://icotherapeutics.com/site/news_media/ico_to_present_at_rodman_renshaw_8th_annual_healthcare_conference/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_welcomes_dr_david_s_boyer_to_strategic_advisory_board/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/news_media/upcoming_events/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_appoints_chief_medical_officer/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_welcomes_dr_jason_slakter_to_strategic_advisory_board/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_to_present_at_epic_in_london_england/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_recruits_leading_ophthalmologist_to_strategic_advisory_brd/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_elects_dr_richard_w_barker_and_william_jarosz_as_indep_dir/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/development_programs/ico007/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/corporate_overview/overview/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/news_media/press_releases/ 2022-04-23T17:14:40+00:00 https://icotherapeutics.com/careers/about_vancouver/ 2022-04-23T17:14:39+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_to_present_at_major_biotechnology_conference/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/world_renowned_retinal_specialist_joins_ico_therapeutics_strategic_advisory/ 2022-04-23T17:09:08+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_selects_isis_pharmaceuticals_to_manufacture_and_supply_ico/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/pace_of_ico_unmatched_by_biotech_competitors/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_announces_strategic_advisory_team/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_to_present_at_biofinance_early_phase_2005/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_named_one_of_canadas_top_investment_prospects/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_to_present_at_bio_investorforum_in_san_francisco/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_to_present_at_biocontact/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/site/news_media/isis_pharmaceuticals_licenses_antisense_drug_to_ico_for_eye_disease/ 2022-04-23T17:09:07+00:00 https://icotherapeutics.com/site/news_media/ico_therapeutics_appoints_expert_immunology_and_ophthalmology_chief_science/ 2022-04-23T17:09:06+00:00 https://icotherapeutics.com/2021/04/28/ico-therapeutics-inc-announces-closing-of-upsized-subscription-receipt-private-placement/ 2021-04-27T21:00:00+00:00 https://icotherapeutics.com/2021/03/15/ico-therapeutics-inc-announces-agreement-for-in-vivo-testing-of-ico-019-on-sars-cov-2/ 2022-04-21T22:16:13+00:00 https://icotherapeutics.com/2021/03/11/ico-therapeutics-inc-announces-warrant-exercises/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2021/01/11/ico-therapeutics-inc-proposes-to-re-price-warrants/ 2021-01-10T21:00:00+00:00 https://icotherapeutics.com/2020/12/31/ico-therapeutics-announces-joint-development-of-ico-019-with-skymount-medical/ 2020-12-30T21:00:00+00:00 https://icotherapeutics.com/2020/11/24/ico-therapeutics-announces-third-quarter-2020-financial-results/ 2020-11-23T21:00:00+00:00 https://icotherapeutics.com/2020/10/26/ico-therapeutics-announces-option-grants/ 2020-10-25T21:00:00+00:00 https://icotherapeutics.com/2020/10/21/ico-therapeutics-inc-announces-that-oral-amphotericin-b-ico-019-results-will-be-highlighted-during-the-american-association-of-pharmaceutical-scientists-aaps-virtual-meeting-october-26-november-2/ 2020-10-20T21:00:00+00:00 https://icotherapeutics.com/2020/08/31/ico-therapeutics-announces-second-quarter-2020-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/07/30/ico-therapeutics-inc-announces-publication-of-oral-amphotericin-b-ico-019-phase-1-safety-study-results-in-prestigious-infectious-diseases-journal/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/07/13/ico-therapeutics-announces-first-quarter-2020-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/06/22/ico-therapeutics-inc-announces-oral-amphotericin-b-ico-019-results-to-be-presented-at-prestigious-american-pharmaceutical-sciences-meeting-and-discussion-updates/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/05/29/ico-therapeutics-inc-announces-q1-interim-filing-update/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/05/19/ico-therapeutics-announces-2019-year-end-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/04/27/ico-therapeutics-inc-announces-annual-filing-update/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/04/15/ico-therapeutics-inc-announces-oral-amphotericin-b-ico-019-update-appointment-of-kishor-wasan-as-director-of-research/ 2020-04-14T21:00:00+00:00 https://icotherapeutics.com/2020/04/15/company-update/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/03/09/ico-therapeutics-announces-leadership-changes/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2020/02/25/ico-therapeutics-successfully-concludes-phase-1b-clinical-study-announces-positive-primary-end-point-for-oral-amphotericin-b/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2020/02/10/ico-therapeutics-announces-completion-of-phase-1b-oral-amphotericin-b-study-dosing-follow-up/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2020/02/10/ico-therapeutics-announces-completion-of-phase-1b-oral-amphotericin-b-study-dosing-and-follow-up/ 2020-02-09T21:00:00+00:00 https://icotherapeutics.com/2020/01/11/ico-therapeutics-inc-proposes-to-re-price-warrants-2/ 2020-01-10T21:00:00+00:00 https://icotherapeutics.com/2020/01/10/ico-therapeutics-announces-option-grants-2/ 2020-01-09T21:00:00+00:00 https://icotherapeutics.com/2020/01/10/ico-therapeutics-announces-option-grants/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2019/12/24/ico-therapeutics-announces-completion-of-sub-license-transfer/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2019/12/11/ico-therapeutics-engages-ora-for-ico-008-ophthalmic-strategy/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2019/12/09/ico-therapeutics-announces-dosing-of-first-full-cohort-in-second-oral-amphotericin-b-study/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2019/11/25/alexion-pharmaceuticals-icos-new-partner-for-the-development-and-commercialization-of-ico-008/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2019/10/28/ico-therapeutics-inc-provides-an-update-regarding-oral-amphotericin-study-marketing-and-partnering-activities/ 2019-10-27T21:00:00+00:00 https://icotherapeutics.com/2019/10/22/ico-therapeutics-inc-provides-a-corporate-update/ 2019-10-21T21:00:00+00:00 https://icotherapeutics.com/2019/08/28/ico-therapeutics-announces-second-quarter-2019/ 2019-08-27T21:00:00+00:00 https://icotherapeutics.com/2019/08/19/ico-therapeutics-inc-announces-the-issuance-of-41200000-units-pursuant-to-its-non-brokered-private-placement/ 2019-08-18T21:00:00+00:00 https://icotherapeutics.com/2019/08/06/ico-therapeutics-provides-corporate-update-2/ 2019-08-05T21:00:00+00:00 https://icotherapeutics.com/2019/06/28/ico-therapeutics-announces-agm-voting-results/ 2022-04-21T22:14:18+00:00 https://icotherapeutics.com/2019/05/30/ico-therapeutics-announces-first-quarter-2019-financial-results/ 2019-05-29T21:00:00+00:00 https://icotherapeutics.com/2013/05/09/ico-therapeutics-announces-overnight-marketed-equity-offering-2/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2019/04/30/ico-therapeutics-announces-2018-year-end-financial/ 2019-04-29T21:00:00+00:00 https://icotherapeutics.com/2019/03/05/ico-therapeutics-inc-announces-the-issuance-of-3600000-units-pursuant-to-its-non-brokered-private-placement/ 2019-03-04T21:00:00+00:00 https://icotherapeutics.com/2019/02/25/ico-therapeutics-inc-announces-the-issuance-of-14400000-units-pursuant-to-its-c1250000-non-brokered-private-placement/ 2019-02-24T21:00:00+00:00 https://icotherapeutics.com/2019/02/19/ico-therapeutics-inc-announces-upsizing-of-non-brokered-private-placement-to-1250000-cdn/ 2019-02-18T21:00:00+00:00 https://icotherapeutics.com/2019/02/19/ico-therapeutics-inc-announces-notice-of-termination-of-sub-license-for-bertilimumab-ico-008/ 2019-02-18T21:00:00+00:00 https://icotherapeutics.com/2019/02/11/ico-therapeutics-inc-announces-the-issuance-of-4000000-units-pursuant-to-its-c750000-non-brokered-private-placement/ 2019-02-10T21:00:00+00:00 https://icotherapeutics.com/2019/02/07/jan312019/ 2019-02-06T21:00:00+00:00 https://icotherapeutics.com/2019/01/31/ico-therapeutics-inc-announces-non-brokered-private-placement-to-raise-c750000/ 2019-01-30T21:00:00+00:00 https://icotherapeutics.com/2018/11/29/ico-therapeutics-announces-third-quarter-2018-financial-results-and-corporate-update/ 2018-11-28T21:00:00+00:00 https://icotherapeutics.com/2018/11/15/ico-therapeutics-provides-corporate-update-including-drug-supply-for-next-oral-amphotericin-b-efficacy-study/ 2018-11-14T21:00:00+00:00 https://icotherapeutics.com/2018/10/23/ico-therapeutics-announces-oral-amphotericin-b-clinical-advisory-board/ 2018-10-22T21:00:00+00:00 https://icotherapeutics.com/2018/10/02/ico-therapeutics-provides-corporate-update/ 2018-10-01T21:00:00+00:00 https://icotherapeutics.com/2018/09/06/ico-therapeutics-announces-additional-positive-pharmacokinetic-results-and-presentation-at-global-investment-conference/ 2018-09-05T21:00:00+00:00 https://icotherapeutics.com/2018/08/29/ico-therapeutics-announces-second-quarter-2018-financial-results-and-corporate-update/ 2018-08-28T21:00:00+00:00 https://icotherapeutics.com/2018/07/16/ico-therapeutics-announces-positive-secondary-endpoint-and-advancement-into-later-stage-clinical-trials-phase-1-oral-amphotericin-b/ 2018-07-15T21:00:00+00:00 https://icotherapeutics.com/2018/06/27/ico-therapeutics-announces-positive-clinical-outcome-primary-endpoint-met-in-phase-1-oral-amphotericin-b-study/ 2018-06-26T21:00:00+00:00 https://icotherapeutics.com/2018/06/20/ico-therapeutics-provides-corporate-update-announces-completion-of-phase-1-recruitment/ 2018-06-19T21:00:00+00:00 https://icotherapeutics.com/2018/05/30/ico-therapeutics-announces-first-quarter-2018-financial-results-and-update-on-phase-1-clinical-trial/ 2018-05-29T21:00:00+00:00 https://icotherapeutics.com/2018/04/24/ico-therapeutics-announces-year-end-2017-financial-results/ 2018-04-23T21:00:00+00:00 https://icotherapeutics.com/2018/04/18/ico-therapeutics-announces-major-milestone-dosing-of-first-patient-for-its-oral-amphotericin-b-phase-1-clinical-study/ 2018-04-17T21:00:00+00:00 https://icotherapeutics.com/2017/11/28/ico-therapeutics-announces-third-quarter-2017-financial-results/ 2017-11-27T21:00:00+00:00 https://icotherapeutics.com/2017/11/22/ico-therapeutics-announces-ethics-approval-for-its-oral-amphotericin-b-phase-1-clinical-study/ 2017-11-21T21:00:00+00:00 https://icotherapeutics.com/2017/09/07/ico-therapeutics-announces-upcoming-presentations-and-meetings/ 2022-04-22T07:56:15+00:00 https://icotherapeutics.com/2017/08/29/ico-therapeutics-announces-second-quarter-2017-financial-results/ 2022-04-22T07:52:11+00:00 https://icotherapeutics.com/2017/08/04/ico-therapeutics-inc-approves-advance-notice-policy/ 2017-08-03T21:00:00+00:00 https://icotherapeutics.com/2017/06/30/ico-therapeutics-announces-election-of-directors/ 2017-06-29T21:00:00+00:00 https://icotherapeutics.com/2017/06/15/ico-therapeutics-announces-pre-ind-meeting-for-novel-glaucoma-asset/ 2017-06-14T21:00:00+00:00 https://icotherapeutics.com/2017/06/12/ico-therapeutics-announces-positive-oral-amphotericin-study/ 2017-06-11T21:00:00+00:00 https://icotherapeutics.com/2017/05/24/ico-therapeutics-announces-first-quarter-2017-financial-results/ 2017-05-23T21:00:00+00:00 https://icotherapeutics.com/2017/04/19/ico-therapeutics-announces-year-end-2016-financial-results/ 2017-04-18T21:00:00+00:00 https://icotherapeutics.com/2017/03/13/ico-therapeutics-inc-announces-no-material-change/ 2017-03-12T21:00:00+00:00 https://icotherapeutics.com/2016/11/28/clarification-ico-therapeutics-announces-positive-study-results-and-significant-advances-related-to-oral-amphotericin-b-program/ 2016-11-27T21:00:00+00:00 https://icotherapeutics.com/2016/11/24/ico-therapeutics-announces-third-quarter-2016-financial-results/ 2016-11-23T21:00:00+00:00 https://icotherapeutics.com/2016/11/15/ico-therapeutics-announces-world-wide-exclusive-option-and-eu-license-rights-with-laboratorios-salvat-for-novel-glaucoma-asset/ 2016-11-14T21:00:00+00:00 https://icotherapeutics.com/2016/08/19/ico-therapeutics-announces-second-quarter-2016-financial-results/ 2016-08-18T21:00:00+00:00 https://icotherapeutics.com/2016/06/27/ico-therapeutics-announces-voting-election-results-from-annual-meeting-of-shareholders-2/ 2016-06-26T21:00:00+00:00 https://icotherapeutics.com/2016/04/14/ico-therapeutics-announces-year-end-2015-financial-results/ 2016-04-13T21:00:00+00:00 https://icotherapeutics.com/2016/02/17/ico-therapeutics-inc-announces-grant-of-stock-options-and-recent-ceo-share-purchases/ 2016-02-16T21:00:00+00:00 https://icotherapeutics.com/2016/01/18/ico-strategic-reorganization/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2015/12/24/ico-therapeutics-announces-changes-to-board-of-directors/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2015/11/24/ico-therapeutics-announces-third-quarter-2015-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2015/10/26/ico-therapeutics-announces-manufacturing-update-for-oral-amp-b-program/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2015/08/26/ico-therapeutics-announces-second-quarter-2015-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2015/06/26/ico-therapeutics-announces-voting-election-results-from-annual-meeting-of-shareholders/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2015/05/28/ico-therapeutics-announces-first-quarter-2015-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2015/04/27/ico-therapeutics-announces-year-end-2014-financial-results/ 2015-04-26T21:00:00+00:00 https://icotherapeutics.com/2014/11/28/ico-therapeutics-announces-third-quarter-2014-financial-results-and-corporate-update/ 2014-11-27T21:00:00+00:00 https://icotherapeutics.com/2014/11/04/ico-therapeutics-announces-oral-amphotericin-presentations-at-aaps/ 2022-04-22T14:01:27+00:00 https://icotherapeutics.com/2014/10/22/ico-therapeutics-announces-advancement-of-oral-amphotericin-b-program/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2014/08/29/ico-therapeutics-announces-second-quarter-2014-financial-results/ 2014-08-28T21:00:00+00:00 https://icotherapeutics.com/2014/08/19/ico-therapeutics-announces-positive-oral-amphotericin-b-study-results/ 2014-08-18T21:00:00+00:00 https://icotherapeutics.com/2014/06/30/ico-therapeutics-announces-director-election-results-from-its-annual-meeting-of-shareholders/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2014/06/09/ico-therapeutics-announces-top-line-primary-endpoint-data-from-ico-007-phase-2-ideal-study-in-diabetic-macular-edema/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2014/05/29/ico-therapeutics-announces-first-quarter-2014-financial-results/ 2014-05-28T21:00:00+00:00 https://icotherapeutics.com/2014/04/29/ico-therapeutics-announces-poster-presentation-at-arvo/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2014/04/24/ico-therapeutics-announces-year-end-2013-financial-results/ 2014-04-23T21:00:00+00:00 https://icotherapeutics.com/2014/03/05/ico-therapeutics-announces-final-eight-month-patient-visit-in-phase-2-ideal-study/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2014/02/25/ico-therapeutics-announces-dtc-approval/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2014/01/27/ico-therapeutics-inc-completes-c6-75-million-equity-financing/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2014/01/22/ico-therapeutics-inc-announces-c6-75-million-equity-financing/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2014/01/21/ico-therapeutics-inc-announces-overnight-marketed-equity-offering/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2013/12/20/ico-therapeutics-begins-trading-on-the-otcqx-marketplace/ 2022-04-22T14:01:27+00:00 https://icotherapeutics.com/2013/12/12/ico-therapeutics-announces-program-and-intellectual-property-advancements-for-oral-amphotericin-b/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/12/05/ico-therapeutics-to-present-at-jefferies-ophthalmic-therapeutic-summit/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/11/27/ico-therapeutics-announces-third-quarter-2013-financial-results/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/11/21/ico-therapeutics-to-present-at-the-6th-annual-ld-micro/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/11/13/ico-therapeutics-announces-warrant-exercise/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/11/07/ico-therapeutics-to-present-at-the-ophthalmology-innovation-summit/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/09/05/ico-therapeutics-grants-options-to-a-director/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/09/04/ico-therapeutics-to-present-at-the-rodman-renshaw-2013-annual-global-investment-conference/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/08/26/ico-therapeutics-announces-second-quarter-2013-financial-results/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/06/18/ico-therapeutics-announces-completion-of-trial-enrollment-and-clinical-update-for-ideal-phase-2-study-for-the-treatment-of-diabetic-macular-edema/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/05/29/ico-therapeutics-announces-first-quarter-2013-financial-results/ 2022-04-22T07:44:04+00:00 https://icotherapeutics.com/2013/05/24/ico-therapeutics-announces-director-election-results-from-its-annual-general-meeting-of-shareholders/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/05/21/ico-therapeutics-closes-3-4-million-financing/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/05/15/ico-therapeutics-to-present-at-the-bloom-burton-co-healthcare-investor-conference/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2013/05/10/ico-therapeutics-to-raise-3-2-million/ 2022-04-22T14:07:09+00:00 https://icotherapeutics.com/2013/04/25/ico-therapeutics-announces-year-end-2012-financial-results/ 2013-04-24T21:00:00+00:00 https://icotherapeutics.com/2013/02/14/ico-therapeutics-ranked-number-one-in-technology-life-sciences-on-2013-tsx-venture-50/ 2013-02-13T21:00:00+00:00 https://icotherapeutics.com/2013/02/05/ico-therapeutics-to-present-at-the-15th-annual-bio-ceo-investor-conference/ 2013-02-04T21:00:00+00:00 https://icotherapeutics.com/2013/01/22/ico-therapeutics-grants-options-to-directors-officers-and-employees-3/ 2013-01-21T21:00:00+00:00 https://icotherapeutics.com/2013/01/03/ico-therapeutics-announces-positive-ico-007-phase-2-clinical-update/ 2022-04-21T22:15:50+00:00 https://icotherapeutics.com/2012/11/29/ico-therapeutics-announces-third-quarter-2012-financial-results/ 2022-04-21T22:14:18+00:00 https://icotherapeutics.com/2012/10/12/ico-therapeutics-oral-amphotericin-b-delivery-system-to-be-presented-at-aaps-with-updated-patent-position/ 2012-10-11T21:00:00+00:00 https://icotherapeutics.com/2012/09/04/ico-therapeutics-to-present-at-the-rodman-renshaw-2012-annual-global-investment-conference/ 2012-09-03T21:00:00+00:00 https://icotherapeutics.com/2012/08/29/ico-therapeutics-announces-second-quarter-2012-financial-results/ 2022-04-21T22:14:17+00:00 https://icotherapeutics.com/2012/07/13/ico-therapeutics-closes-2-55-million-financing/ 2012-07-12T21:00:00+00:00 https://icotherapeutics.com/2012/07/05/ico-therapeutics-to-raise-2-55-million/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2012/07/04/ico-therapeutics-announces-overnight-marketed-equity-offering/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2012/05/31/ico-therapeutics-receives-funding-from-the-government-of-canada-for-the-pre-clinical-and-clinical-development-of-its-oral-amphotericin-b-delivery-system-for-the-treatment-of-hiv-aids/ 2012-05-30T21:00:00+00:00 https://icotherapeutics.com/2012/05/30/ico-therapeutics-announces-first-quarter-2012-financial-results/ 2012-05-29T21:00:00+00:00 https://icotherapeutics.com/2012/04/13/ico-therapeutics-announces-year-end-2011-financial-results/ 2012-04-12T21:00:00+00:00 https://icotherapeutics.com/2012/03/28/ico-therapeutics-and-jdrf-team-up-to-support-phase-ii-clinical-trial-ideal-for-diabetic-macular-edema/ 2012-03-27T21:00:00+00:00 https://icotherapeutics.com/2012/03/27/ico-therapeutics-ceo-to-present-at-retinal-physician-symposium-2012/ 2012-03-26T21:00:00+00:00 https://icotherapeutics.com/2012/03/05/ico-therapeutics-appoints-douglas-janzen-to-board-of-directors/ 2022-04-22T14:07:07+00:00 https://icotherapeutics.com/2012/01/17/ico-therapeutics-retains-crescendo-communications/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/12/04/ico-therapeutics-announces-execution-of-equity-line-facility-agreement/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/11/18/ico-therapeutics-announces-third-quarter-2011-financial-results/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/11/02/ico-therapeutics-closes-1115000-non-brokered-private-placement/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/10/24/ico-therapeutics-oral-amphotericin-b-delivery-system-to-be-presented-at-aaps/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/10/20/ico-therapeutics-ceo-to-present-at-the-ophthalmology-innovation-summit/ 2011-10-19T21:00:00+00:00 https://icotherapeutics.com/2011/09/27/ico-therapeutics-grants-options-to-directors-officers-and-employees-2/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/09/26/ico-therapeutics-and-jdrf-partner-to-investigate-ico-007-in-diabetic-macular-edema/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/09/13/ico-therapeutics-ceo-to-present-act-as-co-chairperson-at-the-4th-annual-drug-repositioning-and-pipeline-enhancement-conference-2/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/09/13/ico-therapeutics-ceo-to-present-act-as-co-chairperson-at-the-4th-annual-drug-repositioning-and-pipeline-enhancement-conference/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/08/29/ico-therapeutics-announces-second-quarter-2011-financial-results/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/08/15/ico-therapeutics-announces-key-ico-007-clinical-development-milestone/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/07/22/ico-therapeutics-announces-resignation-of-john-clement-chief-technology-and-development-officer-and-director/ 2011-07-21T21:00:00+00:00 https://icotherapeutics.com/2011/07/19/ico-therapeutics-engages-the-equicom-group/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/07/12/ico-therapeutics-cmo-to-present-at-the-drug-repositioning-conference/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/06/29/ico-therapeutics-announces-first-quarter-2011-financial-results/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/06/24/ico-therapeutics-executes-bertilimumab-license-with-immune-pharmaceuticals/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/05/31/ico-therapeutics-ceo-to-present-participate-in-panel-at-biofinance-2011/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/05/13/ico-therapeutics-inc-engages-ora-for-ophthalmic-clinical-regulatory-guidance/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/04/29/ico-therapeutics-announces-year-end-2010-financial-results-2/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/04/14/ico-therapeutics-inc-secures-10-million-equity-line-facility-2/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/02/23/ico-therapeutics-inc-ico-007-program-to-be-presented-ceo-to-sit-on-panel-at-retinal-physician-symposium-2011-2/ 2022-04-22T14:07:06+00:00 https://icotherapeutics.com/2011/02/22/ico-therapeutics-inc-completes-ico-007-phase-2-clinical-supply-manufacturing/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/12/24/ico-therapeutics-extends-investor-relations-engagement-with-the-trout-group/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/12/08/ico-therapeutics-grants-license-option-for-bertilimumab-ico-008-systemic-uses-to-immune-pharmaceuticals-for-us33-million-plus-royalties/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/11/26/ico-therapeutics-reports-third-quarter-2010-financial-results/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/10/13/ico-therapeutics-selected-as-canadas-top-10tm-competition-winner-2/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/09/29/ico-therapeutics-oral-amphotericin-program-receives-fda-orphan-drug-status/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/09/22/ico-therapeutics-appoints-infectious-disease-experts-to-scientific-advisory-board/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/08/27/ico-therapeutics-announces-second-quarter-2010-financial-results/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/07/26/ico-therapeutics-inc-receives-health-canada-clearance-to-conduct-phase-ii-dme-trial-with-ico-007/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/05/28/ico-therapeutics-inc-enters-into-investor-relations-engagements-with-the-trout-group-and-sector-speak/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/05/26/ico-therapeutics-announces-first-quarter-2010-financial-results/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/05/25/ico-therapeutics-inc-enters-into-technology-transfer-agreement-with-isis-pharmaceuticals-inc-for-ico-007/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/05/17/ico-therapeutics-ico-007-phase-i-clinical-trial-meets-primary-endpoint/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/04/29/ico-therapeutics-announces-year-end-2010-financial-results/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/04/29/ico-therapeutics-announces-year-end-2009-financial-results/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/04/28/ico-therapeutics-inc-engages-susan-koppy-to-spearhead-ico-007-out-licensing/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/04/22/ico-007-for-diffuse-diabetic-macular-edema-to-be-presented-at-retinal-physician-symposium-2010/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/04/14/ico-therapeutics-inc-secures-10-million-equity-line-facility/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/04/12/ico-therapeutics-inc-recognized-by-biotecanada-with-gold-leaf-award/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/02/23/ico-therapeutics-inc-ico-007-program-to-be-presented-ceo-to-sit-on-panel-at-retinal-physician-symposium-2011/ 2022-04-22T14:07:05+00:00 https://icotherapeutics.com/2010/02/19/ico-007-for-diabetic-macular-edema-to-be-presented-at-angiogenesis-2010-clinical-trials/ 2010-02-18T21:00:00+00:00 https://icotherapeutics.com/2010/02/10/ico-therapeutics-announces-exercise-of-warrants/ 2010-02-09T21:00:00+00:00 https://icotherapeutics.com/2009/12/30/ico-therapeutics-grants-options-to-directors-officers-and-employees/ 2009-12-29T21:00:00+00:00 https://icotherapeutics.com/2009/12/11/ico-therapeutics-provides-phase-1-dme-clinical-trial-update-and-phase-2-trial-guidance/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/12/03/ico-therapeutics-ico-007-overview-to-be-presented-at-the-8th-international-symposium-on-ocular-pharmacology-and-therapeutics/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/11/26/ico-therapeutics-q3-2009-financial-results/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/11/20/ico-therapeutics-completes-final-tranche-of-4000000-brokered-private-placement/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/10/30/ico-therapeutics-completes-first-tranche-of-brokered-private-placement/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/10/20/ico-therapeutics-announces-4000000-brokered-private-placement/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/09/24/ico-therapeutics-signs-collaboration-agreement-with-the-consortium-for-parasitic-drug-development/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/08/21/ico-therapeutics-q2-2009-financial-results/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2009/07/21/ico-therapeutics-appoints-infectious-disease-md-to-scientific-advisory-board/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/07/16/ico-therapeutics-closes-non-brokered-private-placement/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/07/07/ico-therapeutics-diabetic-macular-edema-clinical-trial-update/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/07/02/ico-therapeutics-publishes-review-of-diabetic-retinopathy-treatment/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/06/25/ico-therapeutics-positive-oral-amphotericin-b-data-published-in-the-journal-of-infectious-diseases/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/06/08/shareholders-approve-all-resolutions-at-ico-therapeutics-annual-general-meeting/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/05/29/ico-therapeutics-q1-2009-financial-results/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/04/30/ico-therapeutics-year-end-2008-financial-results/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/04/29/ico-therapeutics-to-present-at-biofinance-2009/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/03/23/ico-therapeutics-oral-anti-parasitic-drug-to-be-presented-at-global-health-symposia/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/03/17/ico-therapeutics-ico-007-second-cohort-results-to-be-presented-at-cleveland-clinic-ocular-conference/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/02/20/ico-therapeutics-grants-options-to-new-directors/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/02/19/ico-therapeutics-ico-007-results-to-be-presented-at-prestigious-ocular-conference/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/02/18/ico-therapeutics-oral-amphotericin-b-published-in-leading-journal/ 2022-04-22T14:07:04+00:00 https://icotherapeutics.com/2009/02/09/ico-therapeutics-closes-1-3-million-private-placement/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2009/01/30/ico-therapeutics-closes-first-tranche-of-non-brokered-private-placement/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/11/18/ico-therapeutics-oral-amphotericin-b-poster-at-aaps/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/11/17/ico-therapeutics-third-quarter-financial-results/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/11/07/ico-therapeutics-oral-amphotericin-b-effective-against-visceral-leishmaniasis/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/10/09/ico-therapeutics-provides-ico-009-oral-amphotericin-b-pharmacokinetic-results/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/10/01/ico-therapeutics-selected-as-canadas-top-10tm-competition-winner/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/09/29/ico-therapeutics-to-present-at-biocontact-quebec/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/09/22/ico-therapeutics-provides-interim-trial-results-diffuse-diabetic-macular-edema/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/09/04/ico-therapeutics-outlines-steps-to-first-ico-009-human-clinical-trial/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/08/28/ico-therapeutics-second-quarter-financial-results/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/07/08/ico-therapeutics-appoints-mr-noel-hall-and-dr-christian-fibiger-to-board/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/06/26/ico-therapeutics-reports-new-ico-009-oral-amphotericin-b-preclinical-results/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/06/09/ico-therapeutics-closes-1140450-financing/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/06/02/ico-therapeutics-announces-1140450-financing/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/05/30/ico-therapeutics-first-quarter-financial-results/ 2022-04-22T14:07:32+00:00 https://icotherapeutics.com/2008/05/07/ico-therapeutics-acquires-worldwide-rights-to-ico-009-oral-amphotericin-b/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/05/05/ico-therapeutics-to-present-at-biofinance-2008/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/04/28/ico-therapeutics-year-end-2007-financial-results/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/04/25/ico-therapeutics-ico-007-diabetic-macular-edema-poster-presentation-at-arvo/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/04/21/ico-therapeutics-announces-ico-009-oral-amphotericin-b-fda-meeting/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/03/17/ico-therapeutics-ico-009-oral-amphotericin-b-published-in-leading-drug-delivery-journal/ 2022-04-22T14:07:03+00:00 https://icotherapeutics.com/2008/03/10/ico-therapeutics-provides-ico-008-phase-ii-clinical-update/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2008/02/27/ico-therapeutics-announces-cmo-invited-to-present-at-international-ocular-conference/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2008/01/21/ico-therapeutics-provides-ico-009-oral-amphotericin-b-update/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2007/12/31/ico-therapeutics-inc-and-beanstalk-capital-ltd-announce-completion-of-arrangement/ 2007-12-30T21:00:00+00:00 https://icotherapeutics.com/2007/10/31/beanstalk-capital-ltd-and-ico-therapeutics-inc-amend-arrangement-agreement/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2007/10/16/beanstalk-capital-ltd-enters-into-arrangement-agreement-with-ico-therapeutics-inc/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2007/10/09/isis-receives-1-25-million-milestone-payment-from-ico-for-initiation-of-phase-1-study-of-ico-007/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2007/01/22/ico-therapeutics-receives-fda-clearance-to-initiate-clinical-trial-in-diabetic-macular-edema/ 2022-04-22T14:07:02+00:00 https://icotherapeutics.com/2007/01/10/ico-therapeutics-announces-licensing-deal/ 2022-04-22T14:07:08+00:00 https://icotherapeutics.com/2007/01/08/cambridge-antibody-tech-licenses-monoclonal-antibody-for-treatment-of-allergy-disorders-to-ico/ 2022-04-22T14:07:01+00:00